Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.98
CBPO's Cash to Debt is ranked higher than
60% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. CBPO: 0.98 )
CBPO' s 10-Year Cash to Debt Range
Min: 0.74   Max: 306.77
Current: 0.98

0.74
306.77
Equity to Asset 0.46
CBPO's Equity to Asset is ranked higher than
60% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CBPO: 0.46 )
CBPO' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.67
Current: 0.46

0.29
0.67
Interest Coverage 76.59
CBPO's Interest Coverage is ranked higher than
58% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 76.59 )
CBPO' s 10-Year Interest Coverage Range
Min: 6.9   Max: 93.8
Current: 76.59

6.9
93.8
F-Score: 4
Z-Score: 5.59
M-Score: -2.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 43.61
CBPO's Operating margin (%) is ranked higher than
97% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CBPO: 43.61 )
CBPO' s 10-Year Operating margin (%) Range
Min: 21.04   Max: 51.58
Current: 43.61

21.04
51.58
Net-margin (%) 29.01
CBPO's Net-margin (%) is ranked higher than
95% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. CBPO: 29.01 )
CBPO' s 10-Year Net-margin (%) Range
Min: 1.06   Max: 26.85
Current: 29.01

1.06
26.85
ROE (%) 29.60
CBPO's ROE (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. CBPO: 29.60 )
CBPO' s 10-Year ROE (%) Range
Min: 2.5   Max: 36.52
Current: 29.6

2.5
36.52
ROA (%) 13.69
CBPO's ROA (%) is ranked higher than
95% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. CBPO: 13.69 )
CBPO' s 10-Year ROA (%) Range
Min: 0.75   Max: 24.56
Current: 13.69

0.75
24.56
ROC (Joel Greenblatt) (%) 50.11
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. CBPO: 50.11 )
CBPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 41.29   Max: 212.58
Current: 50.11

41.29
212.58
Revenue Growth (%) 8.50
CBPO's Revenue Growth (%) is ranked higher than
83% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CBPO: 8.50 )
CBPO' s 10-Year Revenue Growth (%) Range
Min: 8.3   Max: 57.5
Current: 8.5

8.3
57.5
EBITDA Growth (%) 5.50
CBPO's EBITDA Growth (%) is ranked higher than
84% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CBPO: 5.50 )
CBPO' s 10-Year EBITDA Growth (%) Range
Min: 5.5   Max: 72.3
Current: 5.5

5.5
72.3
EPS Growth (%) 15.10
CBPO's EPS Growth (%) is ranked higher than
89% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CBPO: 15.10 )
CBPO' s 10-Year EPS Growth (%) Range
Min: 6.7   Max: 156.1
Current: 15.1

6.7
156.1
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CBPO Guru Trades in Q3 2013

Jim Simons 94,500 sh (+11.44%)
Chuck Royce 2,900 sh (unchged)
» More
Q4 2013

CBPO Guru Trades in Q4 2013

Jim Simons 118,400 sh (+25.29%)
Chuck Royce 2,900 sh (unchged)
» More
Q1 2014

CBPO Guru Trades in Q1 2014

Jim Simons 130,375 sh (+10.11%)
Chuck Royce 2,900 sh (unchged)
» More
Q2 2014

CBPO Guru Trades in Q2 2014

Jim Simons 200,100 sh (+53.48%)
Chuck Royce 2,900 sh (unchged)
Steven Cohen 8,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.40
CBPO's P/E(ttm) is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 23.40 )
CBPO' s 10-Year P/E(ttm) Range
Min: 2.92   Max: 124.23
Current: 23.4

2.92
124.23
P/B 6.21
CBPO's P/B is ranked higher than
73% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. CBPO: 6.21 )
CBPO' s 10-Year P/B Range
Min: 0.84   Max: 6.15
Current: 6.21

0.84
6.15
P/S 6.77
CBPO's P/S is ranked higher than
84% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. CBPO: 6.77 )
CBPO' s 10-Year P/S Range
Min: 0.68   Max: 6.69
Current: 6.77

0.68
6.69
PFCF 25.97
CBPO's PFCF is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 25.97 )
CBPO' s 10-Year PFCF Range
Min: 1.92   Max: 30.83
Current: 25.97

1.92
30.83
EV-to-EBIT 14.89
CBPO's EV-to-EBIT is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 14.89 )
CBPO' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 15.4
Current: 14.89

1.2
15.4
PEG 1.38
CBPO's PEG is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.38 )
CBPO' s 10-Year PEG Range
Min: 0.41   Max: 1.32
Current: 1.38

0.41
1.32
Shiller P/E 47.64
CBPO's Shiller P/E is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 47.64 )
CBPO' s 10-Year Shiller P/E Range
Min: 27.89   Max: 47.14
Current: 47.64

27.89
47.14
Current Ratio 3.05
CBPO's Current Ratio is ranked higher than
67% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CBPO: 3.05 )
CBPO' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.78
Current: 3.05

1.03
5.78
Quick Ratio 1.94
CBPO's Quick Ratio is ranked higher than
63% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. CBPO: 1.94 )
CBPO' s 10-Year Quick Ratio Range
Min: 0.54   Max: 3.92
Current: 1.94

0.54
3.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.50
CBPO's Price/Tangible Book is ranked higher than
79% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. CBPO: 6.50 )
CBPO' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 16.55
Current: 6.5

1.16
16.55
Price/DCF (Projected) 1.88
CBPO's Price/DCF (Projected) is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.88 )
CBPO' s 10-Year Price/DCF (Projected) Range
Min: 0.98   Max: 1.47
Current: 1.88

0.98
1.47
Price/Median PS Value 3.46
CBPO's Price/Median PS Value is ranked higher than
68% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CBPO: 3.46 )
CBPO' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 2.71
Current: 3.46

0.45
2.71
Price/Peter Lynch Fair Value 1.33
CBPO's Price/Peter Lynch Fair Value is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.33 )
CBPO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 1.04
Current: 1.33

0.51
1.04
Price/Graham Number 2.12
CBPO's Price/Graham Number is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 2.12 )
CBPO' s 10-Year Price/Graham Number Range
Min: 0.38   Max: 3.79
Current: 2.12

0.38
3.79
Earnings Yield (Greenblatt) 6.70
CBPO's Earnings Yield (Greenblatt) is ranked higher than
82% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CBPO: 6.70 )
CBPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.5   Max: 84.3
Current: 6.7

6.5
84.3
Forward Rate of Return (Yacktman) 19.69
CBPO's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CBPO: 19.69 )
CBPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 19.9   Max: 35.4
Current: 19.69

19.9
35.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany
China Biologic Products, Inc., is a biopharmaceutical company. It is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products like human albumin and immunoglobulin products in China.
» More Articles for NAS:CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 
China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biol Dec 18 2008 


More From Other Websites
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Sep 18 2014
Nasdaq stocks posting largest percentage increases Sep 17 2014
Regeneron Gets Breakthrough Therapy Status for Eylea Sep 17 2014
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% Sep 10 2014
ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% Sep 08 2014
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% Sep 08 2014
China Biologic to Participate in Upcoming Investor Conferences Sep 05 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 04 2014
China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang Sep 04 2014
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% Sep 04 2014
Can the Rally in China Biologic (CBPO) Shares Continue? Sep 02 2014
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session Aug 29 2014
Aquinox Pharmaceuticals (AQXP) in Focus: Stock Rises 9.1% Aug 28 2014
Sunesis Pharmaceuticals (SNSS) in Focus: Stock Rises 9.9% Aug 28 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 27 2014
China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% Aug 27 2014
Achillion Pharmaceuticals (ACHN) Surges: Stock Adds 9% in Session Aug 27 2014
Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock Moves 10.8% Higher Aug 27 2014
Kite Pharma (KITE) Shows Strength: Stock Rises 17.7% Aug 27 2014
Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% Aug 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK